Vanguard Group Inc. Sells 34,764 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Vanguard Group Inc. cut its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 0.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,263,919 shares of the company's stock after selling 34,764 shares during the period. Vanguard Group Inc. owned 11.40% of Pacira BioSciences worth $99,172,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in PCRX. PNC Financial Services Group Inc. increased its position in Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after acquiring an additional 513 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Pacira BioSciences by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock valued at $184,000 after purchasing an additional 918 shares during the period. Caitlin John LLC increased its stake in Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after buying an additional 1,776 shares during the period. Teacher Retirement System of Texas raised its holdings in Pacira BioSciences by 17.4% during the fourth quarter. Teacher Retirement System of Texas now owns 13,708 shares of the company's stock worth $258,000 after purchasing an additional 2,034 shares in the last quarter. Finally, Global Alpha Capital Management Ltd. lifted its holdings in shares of Pacira BioSciences by 5.7% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 39,900 shares of the company's stock valued at $752,000 after buying an additional 2,160 shares during the period. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Price Performance

PCRX traded down $0.10 during midday trading on Tuesday, hitting $24.88. The company had a trading volume of 34,152 shares, compared to its average volume of 968,353. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.67. The company has a market capitalization of $1.15 billion, a PE ratio of -12.25 and a beta of 0.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm's 50-day simple moving average is $24.70 and its 200-day simple moving average is $20.93.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PCRX. Barclays lifted their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and lifted their target price for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. HC Wainwright boosted their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 target price on shares of Pacira BioSciences in a report on Tuesday, April 8th. Finally, Royal Bank of Canada restated a "sector perform" rating and issued a $18.00 target price on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $26.67.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.